

A flexible approach to Bioanalysis

WHETHER YOUR FOCUS IS SMALL MOLECULES, PROTEIN BIOTHERAPEUTICS, VACCINES, OR GENE

THERAPY, QPS provides a full range of bioanalytical solutions to support drug development from discovery through clinical development and filing.

TIME IS OF THE ESSENCE IN DRUG DEVELOPMENT. CONTACT THE QPS BUSINESS DEVELOPMENT TEAM TODAY!

CALL +1 512 350 2827 EMAIL infobd@qps.com





QPS Bioanalytical Overview

Our scientists come from a variety of backgrounds and can confidently perform the pharmacokinetic (PK), Immunogenecity assessment, pharmacodynamic (PD), and pharmacogenomics (PGx) experiments required by your design.

QPS maintains four advanced bioanalytical facilities in the USA, Netherlands, Taiwan and India, offering strategic solutions to companies with sites or trials overseas and/or wishing to complete studies in Asia and/or India. Benefit from our worldwide resources through which a portfolio of assay to cover your entire global demand in bioanalysis for your clinical studies.

Regulated Bioanalysis

QPS complies with Good Laboratory Practice (GLP) regulations and guidances from the U.S. Food and Drug Administration, other regulatory agencies and incorporates global GLP principles and regulations for successful submission and smooth the way for regulatory acceptance. QPS is a Global CRO with locations around the world to serve the evolving needs of the Pharmaceutical and Biotech industries.

Once the methods, data, and results have been verified, a Quality Assurance Statement is included in every final report. QPS builds robust assays for regulated bioanalysis that are validated in accordance with regulations.

Method Development

QPS works with you to develop assays on the most appropriate technology platform. Before any method development work begins, we sit down with you to review and discuss the assay requirements and intended use, such as:

► Lead optimization vs. Candidate Selection vs. Regulated Bioanalysis

► Liquid chromatography–mass spectrometry (LC-MS/MS) for small molecule drug candidates and their potential metabolites

▶ Ligand Binding Assay (LBA) or LC-MS/MS for peptide and protein drugs

► Ultra-high-performance liquid chromatography coupled to high-resolution mass spectrometry (UHPLC-HRMS) or hybridization-HPLC-fluorescence or HPLCultraviolet (UV) or hybridization-LBA for oligonucleotidebased drugs

- Reverse Transcription Quantitative Polymerase Chain
- ► Reaction (RT-qPCR/qPCR) for mRNA (biotherapeutics and viral or plasmid vectors)

Our staff has considerable experience with conventional matrices (plasma, serum, whole-blood, urine, feces), as well as various animal and human tissues.



QPS is a Global CRO with locations around the world